Contrasting Mirati Therapeutics (MRTX) & Mateon Therapeutics (MATN)

Mateon Therapeutics (OTCMKTS: MATN) and Mirati Therapeutics (NASDAQ:MRTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of recent ratings and price targets for Mateon Therapeutics and Mirati Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mateon Therapeutics 0 1 3 0 2.75
Mirati Therapeutics 0 1 8 0 2.89

Mateon Therapeutics presently has a consensus price target of $1.75, suggesting a potential upside of 993.75%. Mirati Therapeutics has a consensus price target of $14.75, suggesting a potential downside of 40.40%. Given Mateon Therapeutics’ higher probable upside, research analysts plainly believe Mateon Therapeutics is more favorable than Mirati Therapeutics.

Risk & Volatility

Mateon Therapeutics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Mirati Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.

Profitability

This table compares Mateon Therapeutics and Mirati Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Mateon Therapeutics N/A -210.82% -175.67%
Mirati Therapeutics N/A -96.82% -82.29%

Earnings & Valuation

This table compares Mateon Therapeutics and Mirati Therapeutics’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Mateon Therapeutics N/A N/A -$13.65 million ($0.56) -0.29
Mirati Therapeutics N/A N/A -$83.11 million ($3.11) -7.96

Mirati Therapeutics is trading at a lower price-to-earnings ratio than Mateon Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

64.7% of Mirati Therapeutics shares are held by institutional investors. 4.5% of Mateon Therapeutics shares are held by company insiders. Comparatively, 5.1% of Mirati Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Mirati Therapeutics beats Mateon Therapeutics on 7 of the 10 factors compared between the two stocks.

About Mateon Therapeutics

Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

About Mirati Therapeutics

Mirati Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors. Its clinical stage product candidates also comprise sitravatinib, an orally-bioavailable, potent, small molecule spectrum-selective kinase inhibitor, which is in Phase II clinical trials for the treatment of solid tumors, such as NSCLC and metastatic Renal Cell Carcinoma, as well as in Phase Ib clinical trials to treat NSCLC patients with RET, CHR4q12, CBL, and AXL genetic alterations; and mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor, which is in Phase Ib/II clinical trials in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration agreement with Foundation Medicine, Inc. and Guardant Health, Inc. to explore development of their platforms as companion diagnostics for glesatinib. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply